At a glance
ClinicalIndex Comparison Record- ✓Postmenopausal women aged ≥60 years OR <60 with documented postmenopausal status (no menses ≥12 months, or bilateral oophorectomy, or receiving ovarian suppression)
- ✓Early-stage breast cancer Stage I-III treated with neo/adjuvant chemotherapy within 12 months of starting study treatment
- ✓Have evidence of frail health defined as diminished 6-minute walk distance (<400m) at baseline
- ✓No evidence of active/recurrent breast cancer or other serious chronic illnesses
- ✕Cancer-directed chemotherapy, biological therapy, or immunotherapy within 30 days prior to start (with specified exceptions)
- ✕Surgery and/or radiation within last 30 days (except minor outpatient procedures)
- ✕Taking prohibited medications unless safely withheld during dosing intervals
- ✕Herbal/natural medications with possible senolytic properties unless willing to hold 2 days prior and during dosing
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05595499Phase 2RecruitingMonitorUpdated 11mo ago · Completion was 1mo agoA Phase II Randomized Double-Blind Placebo-Controlled Study of Fisetin to Improve Physical Function in Breast Cancer Survivors
In Brief
A Phase 2 clinical trial evaluating Biospecimen Collection, Fisetin, and 3 other interventions for Anatomic Stage I Breast Cancer AJCC v8 and 2 related conditions. Currently recruiting, targeting 88 participants across 7 sites.
Signals
Detailed Summary
This phase II trial tests whether fisetin works to improve physical function in women who have received chemotherapy for stage I-III breast cancer treatment. Fisetin is a naturally occurring substance that is found in strawberries and other foods. Fisetin eliminates cells that have undergone a process called senescence. Senescence is when a cell ages and permanently stops dividing but does not die. Over time, large numbers of these cells build up in tissues throughout the body and can release harmful substances that causes inflammation and damages nearby healthy cells. Studies have shown that chemotherapy causes a build-up of these senescent cells. Giving fisetin may eliminate senescent cells and improve physical function in postmenopausal women who have received chemotherapy for breast cancer.
Study Details
Timeline
Interventions
Undergo collection of blood samples
Given PO
Given PO
Ancillary studies
Ancillary studies